E&L Failure after packaging change: packaging integrity and CCIT justification


Published on 29/12/2025

Understanding E&L Failures Post-Packaging Changes: A Structured Investigation Approach

In pharmaceutical manufacturing, especially within the realm of ophthalmic dosage forms, the integrity of packaging is crucial to product quality and patient safety. When an Extractables and Leachables (E&L) failure arises following a packaging change, it signifies potential risks that warrant immediate investigation. This article provides a comprehensive framework for conducting a structured investigation into E&L failures after packaging changes, aimed at helping pharmaceutical professionals navigate the complexities of deviation management, root cause analysis, and corrective actions.

After reading this article, you will have the procedural knowledge necessary to effectively identify symptoms, hypothesize potential causes, and implement a rigorous investigation workflow to uncover the root cause of E&L failures post-packaging modifications. You will also learn about CAPA strategies and inspection readiness, ensuring regulatory compliance throughout the process.

Symptoms/Signals on the Floor or in the Lab

When E&L failures occur after a packaging change,

certain symptoms or signals may be observed. These can manifest in various ways, including:

  • Out of Specification (OOS) Results: Laboratory testing may yield E&L results that exceed acceptable limits as defined in the product specifications.
  • Product Complaints: Increased reports from healthcare professionals or patients regarding adverse outcomes linked to product use.
  • Inconsistencies in Quality Control Analyses: Variations in testing results that correlate with the timing of packaging changes.
  • Unexpected Changes in Stability Data: Deterioration of product stability observed during routine stability studies.

It is in these moments that an immediate and thorough investigation is critical. Each symptom can serve as a catalyst for identifying potential systemic issues related to the packaging change.

Likely Causes

When assessing causes of E&L failures, it is beneficial to categorize potential issues using the “5 M” approach: Materials, Method, Machine, Man, Measurement, and Environment. Understanding these categories can streamline the investigation. Below are potential causes classified accordingly:

Category Potential Cause
Materials Use of non-compliant materials in the new packaging that leach substances into the drug product.
Method Changes in handling or storage procedures during packaging that could introduce contaminants.
Machine Malfunction or calibration issues with the packaging equipment which may compromise packaging integrity.
Man Insufficient training of personnel on the new packaging process, leading to deviations from established protocols.
Measurement Inaccurate analytical methods used for E&L testing not validating the new packaging.
Environment Changes in environmental conditions such as temperature and humidity that impact packaging integrity.
Pharma Tip:  Ccit Failure after packaging change: packaging integrity and CCIT justification

Immediate Containment Actions (First 60 Minutes)

In the event of an E&L failure upon discovering OOS results or other critical signals, immediate containment actions are necessary to mitigate risks and prevent further complications:

  1. Quarantine Affected Batches: Segregate all batches associated with the packaging change to prevent their distribution.
  2. Notify Quality Assurance (QA): Promptly inform your QA team to initiate a controlled investigation and inform regulatory authorities if necessary.
  3. Conduct a Preliminary Assessment: Examine production records, batch documentation, and any recent package testing results to identify potential correlations.
  4. Implement Temporary Controls: If feasible, substitute the affected packaging with proven alternatives until further investigation is complete.
  5. Engage Cross-Functional Teams: Involve key stakeholders from QA, manufacturing, and regulatory affairs to ensure all perspectives are considered in the response.

Investigation Workflow

Initiating a structured investigation is critical to uncovering the root cause of E&L failures. The workflow should encompass specific stages, as detailed below:

  1. Data Collection: Gather relevant data, including batch records, testing results, equipment logs, and previous deviations. Focus particularly on data that aligns with the timing of the packaging change.
  2. Data Analysis: Analyze the collected data to discern any patterns or anomalies. Compare E&L results against historical data to assess deviations. Review any equipment downtime or anomalies during production.
  3. Hypothesis Development: Based on data analysis, formulate potential hypotheses regarding the cause of the failure. Engage team members to brainstorm possible scenarios.
  4. Testing of Hypotheses: Prioritize hypotheses for testing and verification. This may include additional E&L testing on retained samples, or replicating conditions to evaluate the proposed causes.
  5. Documentation: Ensure all findings, analyses, and conclusions are fully documented. This is essential for ongoing remediation and regulatory compliance.

Root Cause Tools

Utilizing effective root cause analysis tools can substantially enhance the investigation process. Here are key methods:

  • 5 Why Analysis: A simple yet effective method that involves asking “why” repeatedly (typically five times) to drill down into the layers of a problem until reaching the root cause.
  • Fishbone Diagram (Ishikawa): This tool helps categorize potential causes across different dimensions, facilitating a visual representation that can reveal complex interrelationships among causes.
  • Fault Tree Analysis (FTA): FTA utilizes a top-down approach to map out the various fault paths leading to the failure event, helping to pinpoint critical pathways that require more attention.

Choosing the right root cause tool should depend on the complexity of the problem and the resources available. For straightforward issues, the 5 Why approach may suffice, while more intricate scenarios could benefit from a Fishbone Diagram or FTA.

Pharma Tip:  Fill Volume Variability at stability pull: risk assessment for sterility assurance

CAPA Strategy

Once the root cause is determined, a robust Corrective and Preventive Action (CAPA) strategy must be implemented. This strategy typically involves:

  1. Correction: Implement immediate actions to address the failure, including halting production activities with the affected packaging and communicating appropriately with stakeholders.
  2. Corrective Action: Focus on identifying long-term fixes that address the root cause identified during the investigation. This might involve retraining personnel, changing suppliers, or validating alternate packaging materials.
  3. Preventive Action: Put in place measures that will prevent recurrence, such as updating SOPs, enhancing quality controls, and modifying the change control process to ensure rigorous evaluations of future packaging changes.

Control Strategy & Monitoring

An effective control strategy will assist in the ongoing monitoring of packaging integrity once corrective actions are enacted. Consider the following monitoring elements:

  • Statistical Process Control (SPC) and Trending: Implement SPC techniques to continuously monitor key metrics related to packaging performance, and regularly review trends to identify any deviations.
  • Regular Sampling: Increase sampling frequency for E&L testing based on the criticality of the product/system affected. Ensure that an adequate number of samples are being tested under varied conditions to capture all potential failures.
  • Alarms and Alerts: Set up systems to generate alerts for any deviations from established E&L thresholds during routine tests.
  • Verification: Schedule periodic verification activities to confirm that product integrity is consistently maintained over time.

Validation / Re-qualification / Change Control Impact

Recognizing when validation, re-qualification, or change control actions are needed is vital following an E&L failure. Key considerations include:

  • Assess the need for re-validation of affected products based on root causes identified during the investigation.
  • Evaluate the impact of the packaging change on established controls, and adjust the validation plan accordingly to capture additional risks.
  • Enhance change control procedures to ensure that future packaging modifications undergo rigorous assessments and validations prior to implementation.

Inspection Readiness: What Evidence to Show

Demonstrating inspection readiness is critical for regulatory compliance. Key evidence pertinent to the investigation should include:

Related Reads

  • Records and Logs: Maintain comprehensive and accessible records of all data collected during the investigation, including batch production records, testing logs, and CAPA documentation.
  • Batch Documentation: Be prepared to present detailed batch documentation that reflects the timelines, quantities, and any incidents correlated with the E&L failure.
  • Deviations and CAPA Reports: Ensure that deviations regarding E&L testing and corrective actions taken are well documented, clear, and retrievable.
  • Training Records: Provide evidence of training provided to personnel on new packaging procedures and changes to protocols.
Pharma Tip:  Pet Failure for multi-dose products: how to avoid repeat 483 observations

FAQs

What is an E&L Failure?

An E&L failure refers to a situation where the levels of extractables and leachables from packaging materials exceed predefined acceptable limits during testing.

What causes E&L failures?

E&L failures can be caused by a variety of factors, including changes in packaging materials, production methods, environmental conditions, or inadequate quality controls.

How can I prevent E&L failures in the future?

To prevent E&L failures, thorough validation of packaging materials, stringent quality control measures, and adherence to robust change control processes are essential.

What should I do if I suspect an E&L failure?

Immediately initiate containment actions by quarantining affected batches, notifying QA, and starting a comprehensive investigation to determine the root cause.

What regulatory guidelines should I follow regarding E&L testing?

Refer to guidelines established by regulatory agencies like the FDA, EMA, and ICH for comprehensive recommendations on E&L testing and packaging controls.

How often should E&L testing be conducted?

The frequency of E&L testing should be determined based on risk assessments, the significance of packaging changes, and product lifecycle considerations.

What are the key components of an effective CAPA strategy?

An effective CAPA strategy should include steps for correction, corrective action, and preventive action, each of which targets root causes and aims to avoid recurrence.

Why is documentation critical during an E&L investigation?

Documentation is crucial as it provides evidence for regulatory compliance, tracks the investigation process, and forms the basis for corrective actions and future improvements.

When is re-validation or re-qualification necessary?

Re-validation or re-qualification is necessary when significant changes to the packaging process or materials occur, particularly after E&L failures are identified.

How can I ensure my team is inspection-ready?

To ensure inspection readiness, maintain comprehensive records, ensure proper training for staff, and regularly conduct internal audits to assess compliance with established protocols.

What tools can assist in root cause analysis for E&L failures?

Common tools include 5 Why analysis, Fishbone diagrams, and Fault Tree analysis, each serving to identify and define potential causes of the failures.

How can quality control influence E&L outcomes?

Effective quality control measures ensure that raw materials and packaging processes are monitored, leading to minimized risks of E&L failures and compliance with specifications.